Prevention and treatment of thromboembolic events in medical patients and new anticoagulants

Acta Clinica Belgica

Volumn 64, Issue 6, 2009, Pages 547-552

  Balaratnam, S ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Acute medical illness; Anticoagulant; Thromboprophylaxis; Venous thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN ETEXILATE; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RIVAROXABAN; THROMBIN INHIBITOR;

ANTICOAGULANT THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; PATIENT MONITORING; PRIMARY PREVENTION; QUALITY OF LIFE; SECONDARY PREVENTION; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

EID: 75149119814     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1179/acb.2009.093     Document Type: Conference Paper

References (42)

1. Cohen AT (VTE Impact Assessment Group in Europe, VITAE). Venous Thromboembolism (VTE) in Europe: The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007; 98:756-76
2. Shojania KG et al. Making Healthcare Safer: A Critical Analysis of Patient Safety Practices. Evidence Report No. 43 from the Agency for Healthcare Research and Quality. AHRQ Publication No. 01-E058; (2001)
3. Clagett, GP et al. Prevention of venous thromboembolism. Chest. 1998; 114(suppl),531S-560S
4. Sandler DA et al. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med 1989; 82: 203-205.
5. Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 1995; 108: 978-981.
6. Alikhan et al. Fatal pulmonary embolism in hospitalised patients: a necropsy review. Journal of Clinical Pathology 2004;57:1254-1257
7. Cohen AT, Edmonson RA, Phillips MJ, et al. The changing pattern of venous thromboembolic disease. Haemostasis 1996;26:65-71.
8. Health Select Committee Second Report. UK Parliament .2005. Ch2.
9. Leizorovicz A. Long-term consequences of deep vein thrombosis. Haemostasis. 1998;28 Suppl 3:1-7.
10. Seagroatt V et al. Elective total hip replacement: incidence, emergency readmission rate, and postoperative mortality. BMJ. 1991 Dec 7;303(6815):1431-5.
11. Prandoni et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica. 1997 Jul-Aug;82(4):423-8.
12. Bergqvist D. New approaches to prevention of deep vein thrombosis. Thromb Haemost. 1997 Jul;78(1):684-8.
13. Hirsh J et al. Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. Circu lation. 1996 Jun 15;93(12):2212-45.
14. Collins et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med. 1988 May 5;318(18):1162-73.
15. Nielsen HK et al. 178 fatal cases of pulmonary embolism in a medical department. Acta Med Scand. 1981;209(5):351-5.
16. Hauch O et al. Fatal pulmonary embolism associated with surgery. An autopsy study. Acta Chir Scand. 1990 Nov-Dec;156(11-12):747-9.
17. Sperry KL et al. Toward a population-based assessment of death due to pulmonary embolism in New Mexico. Hum Pathol. 1990 Feb;21(2):159-65.
18. Samama MM et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999 Sep 9;341(11):793-800.
19. Leizorovicz A et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembo-lism in acutely ill medical patients. Circulation. 2004 Aug 17;110(7):874-9.
20. Cohen AT et al (ARTEMIS Investigators). Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006; 332: 325-329
21. Cohen et al. VTE risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. The Lancet, 2 February 2008; Volume 371(9610): 387-394.
22. Bates SM et al. Treatment of venous thromboembolism. Thromb Haemost. 1999 Aug;82(2):870-7.
23. Kearon C. Initial treatment of venous thromboembolism. Thromb Haemost. 1999 Aug;82(2):887-91.
24. Turkstra F et al. The treatment of deep vein thrombosis and pulmonary embolism. Thromb Haemost. 1997 Jul;78(1):489-96
25. Vena caval filters for the prevention of PE. Cochrane Database Syst Rev. Oct 2007
26. Hutten B et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000;18:3078-83.
27. Ridker PM et al. Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism. April 10,2003; 15 (348):1425-1434
28. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for longterm prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349(7):631-639.
29. Barritt DW et al. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet. 1960 Jun 18;1(7138):1309-12.
30. Ginsberg JS. Management of venous thromboembolism. N Engl J Med. 1996 Dec 12;335(24):1816-28.
31. Gallus A et al. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet. 1986 Dec 6;2(8519):1293-6.
32. Hull, RD et al. (American-Canadian Thrombosis Study Group). Low-Molecular-Weight Heparin vs Heparin in the Treatment of Patients With Pulmonary Embolism. Arch Intern Med 2000; (160): 229-236
33. Levine, M et al A Comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334,677-681
34. Dolovich, LR et al A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000;160,181-188
35. Geerts et al. Prevention of VTE. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. CHEST 2004; 126:338S-400S
36. Donat F et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 2002;41 (suppl):1-9)
37. Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of PE. N Engl J Med. 2003,349: 1695-1702
38. Büller HR, Davidson BL, Decousus H; et al, Matisse Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep vein thrombosis: a randomized trial. Ann Intern Med. 2004;140(11):867-873
39. British National Formulary 58, 2009
40. Xarelto® Summary of Product Characteristics - EU, October 200841.
41. Koopman, MM, Prandoni, P, Piovella, F, et al Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home: the Tasman Study Group. N Engl J Med 1996;334,682-
42. Lee, AYet al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349,146-153.